Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2016 2
2017 2
2019 2
2020 4
2021 4
2022 5
2023 7
2024 10
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean M. fadayomi (1 results)?
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2024 Jun;131(6):708-723. doi: 10.1016/j.ophtha.2023.12.026. Epub 2023 Dec 28. Ophthalmology. 2024. PMID: 38158159 Free article. Clinical Trial.

Mean CST reductions were greater (YOSEMITE/RHINE weeks 92/96/100 average: faricimab every 8 weeks -216.0/-202.6 m, faricimab T&E -204.5/-197.1 m, aflibercept every 8 weeks -196.3/-185.6 m), and more patients achieved absence of DME (CST < 325 mum; Y

…
Mean CST reductions were greater (YOSEMITE/RHINE weeks 92/96/100 average: faricimab every 8 weeks -216.0/-202.6 m, faricimab T&E …
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.
Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, Wolf S, Gupta V, Ngah NF, Liew G, Tuli R, Tadayoni R, Dhoot D, Wang L, Bouillaud E, Wang Y, Kovacic L, Guerard N, Garweg JG. Brown DM, et al. Am J Ophthalmol. 2022 Jun;238:157-172. doi: 10.1016/j.ajo.2022.01.004. Epub 2022 Jan 14. Am J Ophthalmol. 2022. PMID: 35038415 Free article. Clinical Trial.

RESULTS: At Week 52, brolucizumab 6 mg was noninferior (NI margin 4 letters) to aflibercept in mean change in BCVA from baseline (KESTREL: +9.2 letters vs +10.5 letters; KITE: +10.6 letters vs +9.4 letters; P < .001), more subjects achieved central subfield thickness (CSFT) &l

…
RESULTS: At Week 52, brolucizumab 6 mg was noninferior (NI margin 4 letters) to aflibercept in mean change in BCVA from baseline (KESTREL: + …
Report of the 2023 Mary Tyler Moore Vision Initiative Workshop.
Levine SR, Markel DS, Myers MG, Barunas R, Sun JK, Chang DS, Maguire MG, Vujosevic S, Fort PE, Atkinson M, Baschiera F, Gates C, Hunt JM, King GL, Kretzler M, Lai P, Lewis D, Luhmann UFO, McLeod S, Oxenreiter C, Unsworth S, Chambers W, Aiello LP, Ehrlich J, German CL, Tadayoni R, Wolf RM, Silva P, Carlson E, Gott B, Oxenreiter M, Sexton N, Das A, Gardner TW. Levine SR, et al. Transl Vis Sci Technol. 2025 Jul 1;14(7):11. doi: 10.1167/tvst.14.7.11. Transl Vis Sci Technol. 2025. PMID: 40679331 Free PMC article.
Macular holes with minimal diameter greater than 650 m close in 85% of cases after vitrectomy and ILM peeling with visual benefit.
Bencheqroun M, Couturier A, Chehaibou I, Tadayoni R, Philippakis E. Bencheqroun M, et al. Eye (Lond). 2024 Dec;38(17):3341-3346. doi: 10.1038/s41433-024-03302-y. Epub 2024 Sep 6. Eye (Lond). 2024. PMID: 39251889 Free PMC article.
The mean minimum horizontal diameter was 777 108 m (650-1114). It ranged between 650 and 800 m in 40 eyes (54%) and was 800 m in 34 eyes (46%). The closure rate was 77% (57/74) after primary surgery and was significantly higher in MH between 650 and 80 …
The mean minimum horizontal diameter was 777 108 m (650-1114). It ranged between 650 and 800 m in 40 eyes (54%) and was …
Choroidal thickness and vessel pattern in myopic eyes with dome-shaped macula.
Negrier P, Couturier A, Gaucher D, Touhami S, Le Guern G, Tadayoni R, Gaudric A, Philippakis E. Negrier P, et al. Br J Ophthalmol. 2022 Dec;106(12):1730-1735. doi: 10.1136/bjophthalmol-2021-319066. Epub 2021 Jun 28. Br J Ophthalmol. 2022. PMID: 34183323
Compared with the 11 eyes (41%) with horizontal DSM, the 16 eyes (59%) with vertical DSM had a shorter axial length (25.8 2 mm vs 28.3 2.5 mm; p=0.01), a higher mean macular bulge height (624.4 207 m vs 255.4 160.3 m; p=0.0001) and a thicker CT (183.1 91.1 m …
Compared with the 11 eyes (41%) with horizontal DSM, the 16 eyes (59%) with vertical DSM had a shorter axial length (25.8 2 mm vs 28.3 2.5 m …
Assessment of Cardiovascular Disease Among Predominantly Black Gout Patients.
Chandrakumar HP, Puskoor AV, Chillumuntala S, Sharif S, Mora DC, Gupta T, Tadayoni A, Zonnoor SL, Celiker P, Yakoubovitch S, Tsai A, Chiu C, Kazi A, Freilich M, Saleh A, Moon SJ, Cruickshank K, Li S, Katz J, Eichler J, Salciccioli L, McFarlane IM. Chandrakumar HP, et al. J Clin Rheumatol. 2023 Jun 1;29(4):202-206. doi: 10.1097/RHU.0000000000001948. Epub 2023 Mar 6. J Clin Rheumatol. 2023. PMID: 36881837
RESULTS: Four hundred seventy-one patients with gout had a mean age of 63.7 0.5 years; 89% were Black, 63% were men, and mean body mass index was 31.3 0.4 kg/m 2 . Hypertension, diabetes mellitus, and dyslipidemia were present in 89%, 46%, and 52%, respectively. ...
RESULTS: Four hundred seventy-one patients with gout had a mean age of 63.7 0.5 years; 89% were Black, 63% were men, and mean body mass in …
Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER.
Sadda S, Sarraf D, Khanani AM, Tadayoni R, Chang AA, Saffar I, Gedif K, Wong DT. Sadda S, et al. Br J Ophthalmol. 2024 May 21;108(6):852-858. doi: 10.1136/bjo-2023-323577. Br J Ophthalmol. 2024. PMID: 37669850 Free PMC article. Clinical Trial.
In eyes with lower SHRM measurements at week 12, mean BCVA gains from baseline were higher at week 96 (<200 m, +6.47 Early Treatment Diabetic Retinopathy Study letters; 200 m, +3.10 letters). Eyes with the lowest SHRM thickness variability from week 12 to week …
In eyes with lower SHRM measurements at week 12, mean BCVA gains from baseline were higher at week 96 (<200 m, +6.47 Early Treatm …
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
31 results